Colon dysbiosis and chronic kidney disease


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The colon microbiota was investigated in patients with chronic kidney disease (CKD) and manifestations of renal failure. Colon dysbiosis was detected in all the patients, which was manifested predominantly by the proteolytic flora of enteropathogenic Escherichia coli, Enterobacter spp/Citrobacter spp., and clinically by the symptoms of intestinal dyspepsia (symptoms of tympanism and constipation). The use of Laminolact in CKD patients normalizes the colon microbiota and reduces the manifestations of renal failure.

全文:

受限制的访问

作者简介

M. Barilko

L.G. Sokolov Clinical Hospital One Hundred and Twenty-Two, Federal Biomedical Agency

Saint Petersburg

P. Seliverstov

I.I. Mechnikov North-Western State Medical University

Email: seliverstov-pv@yandex.ru
Candidate of Medical Sciences Saint Petersburg

V. Radchenko

I.I. Mechnikov North-Western State Medical University

Professor, MD Saint Petersburg

参考

  1. Bello A., Levin A., Tonelli M. et al. Assessment of Global Kidney Health Care Status // JAMA. - 2017; 317 (18): 1864-81.
  2. Смирнов А.В., Шилов Е.М., Добронравов В.А. и др. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Национальные рекомендации / СПб: Издательство «Левша», 2012; 51 с.
  3. Wong J., Piceno Y., De Santis T. et al. Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD // Am. J. Nephrol. - 2014; 39: 230-7.
  4. McIntype C., Harrison L., Eldehni M. et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease // Clin. J. Am. Soc. Nephrol. - 2011; 6 (1): 133-41.
  5. Anders H., Andersen K., Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease // Kidney Int. - 2013; 83: 1010-6.
  6. Evenepoel P., Poesen R. The gut-kidney axis // Pediatr. Nephrol. - 2016; 32 (11): 2005-14.
  7. Meijers B., Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression // Nephrol. Dial. Transplant. - 2011; 26: 759-61.
  8. Cosota C., Rocchetti M., Sabatino A. et al. Microbiota issue in CKD: how promising are gut-targeted approaches? // J. Nephrol. - 2018. DOI: 10.1007/ s40620-018-0516-0 [Epub ahead of print]
  9. Pahl M., Vaziri N. The chronic kidney disease - colonic axis // Seminars in Dialysis. - 2015; 1-5.
  10. Vaziri N.D. Gut microbial translocation in the pathogenesis of systemic inflammation in patients with end-stage renal disease // Dig. Dis. Sci. - 2014; 59 (9): 2020-2.
  11. Актуальные вопросы коррекции микробиоценоза кишечника. Учебно-методическое пособие. Под ред. В.Г. Радченко, В.П. Добрица, П.В. Селиверстова, Л.А. Тетериной, Е.А. Чихачевой / СПб, 2012; 20 с.
  12. Khodor S., Shatat I. Gut microbiome and kidney disease: a bidirectional relationship // Pediatr. Nеphrol. - 2017; 32: 921-31.
  13. Pan W., Kang Y. Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies // Int. Urol. Nephrol. -2018; 50 (2): 289-99.
  14. Mafra D., Lobo J., Barros A. et al. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease // Future Microbiology. - 2014; 9 (3): 399-410.
  15. Khoury T., Tzukert K., Abel R. et al. The gut-kidney axis in chronic renal failure: A new potential target for therapy // Hemodialysis International. - 2017; 21: 323-34.
  16. Beto J., Ramirez W., Bansal V. Medical nutrition therapy in adults with chronic kidney disease: integrating evidence and consensus into practice for the generalist registered dietitian nutritionist // J. Acad. Nutr. Diet. - 2014; 114 (7): 1077-87.
  17. Средства для коррекции дисбиоза: функциональное питание. Под ред. А.Н. Суворова / СПб, 2015; 15 с. [Medications for the correction of dysbiosis: functional nutrition. Ed. A. Suvorov / SPb, 2015; 15 s. (in Russ.)].
  18. Sabatino A. et al. Alterations of intestinal barrier and microbiota in chronic kidney disease // Nephrol. Dial. Transplant. - 2015; 30: 924-33.
  19. Wong J., Piceno Y., De Santis T. Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD // Am. J. Nephrol. - 2014; 39: 230-7.
  20. Айтбаев К.А., Муркамилов И.Т., Калиев Р.Р. Хроническая болезнь почек: патофизиологическая роль дисбиоза кишечника и ренопротективная эффективность вмешательств по его модуляции // Рос. мед. журн. - 2016; 22 (3): 157-62
  21. Vaziri N. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity // Curr. Opin. Nephrol. Hypert. - 2012; 21: 587-92.
  22. Wyss M., Kaddurah-Daouk R. Creatine and creatinine metabolism // Physiological Rev. - 2000; 80 (3): 1119-21, 1173-6.
  23. Радченко В.Г., Селиверстов П.В., Загородникова К.А. и др. Пат.2646467 РФМПК A61K 35/66; A61P 13/12. Способ лечения больных хронической болезнью почек С3-С5 на додиализном этапе, исключая пиелонефриты, мочекаменную болезнь. №2017113189; Заявл. 17.04.2017; Опубл. 5.03.2018. Бюл. №7: 18 с.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##